The therapeutic indications of FEIBA1

FEIBA is indicated for:

These uses also include:

FEIBA is also used in surgical interventions in haemophilia A and B patients with inhibitors.

Other uses:

  • In three cases, FEIBA was also used in patients with an inhibitor to von-Willebrand Factor.
  • FEIBA is also used in combination with Factor VIII concentrate for long-term therapy to avoid breakthrough bleeding during ITI

The approved indications for FEIBA vary from country to country. Therefore, please always refer to the prescribing information approved in your country and use the product in line with the approved local prescribing information.

Important Safety Information

FEIBA must not be used in the following situations if therapeutic alternatives to FEIBA are available:

  • Hypersensitivity to the product or any of the components.
  • Disseminated Intravascular Coagulation (DIC).
  • Acute thrombosis or embolism (including myocardial infarction).

Thrombotic and thromboembolic events, including disseminated intravascular coagulation (DIC), venous thrombosis, pulmonary embolism, myocardial infarction, and stroke have occurred in the course of treatment with FEIBA, particularly after administration of doses above the maximum daily dose and/or prolonged application or in patients with other risk factors for thromboembolic events.
As with any intravenously administered plasma product, allergic type hypersensitivity reactions may occur; patients should be informed of the early signs of hypersensitivity reactions. When medicines prepared from human blood or plasma are administered, the possibility of passing on infection cannot be totally excluded. This also applies to any unknown or emerging viruses or other types of infections.
Administration of FEIBA to patients with inhibitors may result in an initial anamnestic rise in inhibitor levels. Upon continued administration of FEIBA, inhibitors may decrease over time. Clinical and published data suggest that the efficacy of FEIBA is not reduced.

Reference

  1. 1. FEIBA Summary of Product Characteristics 2010.

Rapid onset and sustained activity

FEIBA stops bleeds quickly and offers a long dosing interval. Read more

Proven efficacy

Discover the efficacy of FEIBA in both on-demand and prophylaxis treatment. Read more

Integral to inhibitor management

Learn how FEIBA is integral to the management of patients with inhibitors. Read more

Publications

Access articles related to managing haemophilia patients with inhibitors. Read more